Adipose-derived mesenchymal stromal/stem cells in systemic sclerosis: Alterations in function and beneficial effect on lung fibrosis are regulated by caveolin-1

Abstract

The potential value of mesenchymal stromal/stem cell therapy in treating skin fibrosis in scleroderma (systemic sclerosis) and of the caveolin-1 scaffolding domain peptide in treating lung, skin, and heart fibrosis is known. To understand how these observations may relate to differences between mesenchymal stromal/stem cells from healthy subjects and subjects with fibrosis, we have characterized the fibrogenic and adipogenic potential of adipose-derived mesenchymal stromal/stem cells from systemic sclerosis patients, from mice with fibrotic lung and skin disease induced by systemic bleomycin treatment, and from healthy controls. Early passage systemic sclerosis adipose-derived mesenchymal stromal/stem cells have a profibrotic/anti-adipogenic phenotype compared to healthy adipose-derived mesenchymal stromal/stem cells (low caveolin-1, high α-smooth muscle actin, high HSP47, low pAKT, low capacity for adipogenic differentiation). This phenotype is mimicked by treating healthy adipose-derived mesenchymal stromal/stem cells with transforming growth factor beta or caveolin-1 small interfering RNA and is reversed in systemic sclerosis adipose-derived mesenchymal stromal/stem cells by treatment with caveolin-1 scaffolding domain peptide, but not scrambled caveolin-1 scaffolding domain peptide. Similar results were obtained with adipose-derived mesenchymal stromal/stem cells from systemic sclerosis patients and from bleomycin-treated mice, indicating the central role of caveolin-1 in mesenchymal stromal/stem cell differentiation in fibrotic disease.

Keywords

Caveolin-1 fibrosis adipogenesis mesenchymal stem cells scleroderma

Get full access to this article

View all access options for this article.

References

Friedenstein

Gorskaja

Kulagina

NN.

Fibroblast precursors in normal and irradiated mouse hematopoietic organs. Exp Hematol 1976; 4(5): 267–274.

Maria

Maumus

Le Quellec

et al . Adipose-derived mesenchymal stem cells in autoimmune disorders: state of the art and perspectives for systemic sclerosis. Clin Rev Allergy Immunol 2017; 52(2): 234–259.

Del Papa

Zaccara

DiLuca

et al . Adipose-derived cell transplantation in systemic sclerosis: state of the art and future perspectives. J Scleroderma Relat Disord 2017; 2(1): 33–41.

Kern

Eichler

Stoeve

et al . Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 2006; 24(5): 1294–1301.

Gabrielli

Avvedimento

Krieg

Scleroderma. N Engl J Med 2009; 360(19): 1989–2003.

Maria

Toupet

Maumus

et al . Human adipose mesenchymal stem cells as potent anti-fibrosis therapy for systemic sclerosis. J Autoimmun 2016; 70: 31–39.

Christopeit

Schendel

Foll

et al . Marked improvement of severe progressive systemic sclerosis after transplantation of mesenchymal stem cells from an allogeneic haploidentical-related donor mediated by ligation of CD137L. Leukemia 2008; 22(5): 1062–1064.

Keyszer

Christopeit

Fick

et al . Treatment of severe progressive systemic sclerosis with transplantation of mesenchymal stromal cells from allogeneic related donors: report of five cases. Arthritis Rheum 2011; 63(8): 2540–2542.

Guiducci

Porta

Saccardi

et al . Autologous mesenchymal stem cells foster revascularization of ischemic limbs in systemic sclerosis: a case report. Ann Intern Med 2010; 153(10): 650–654.

10.

Scuderi

Ceccarelli

Onesti

et al . Human adipose-derived stromal cells for cell-based therapies in the treatment of systemic sclerosis. Cell Transplant 2013; 22(5): 779–795.

11.

Del Papa

Caviggioli

Sambataro

et al . Autologous fat grafting in the treatment of fibrotic perioral changes in patients with systemic sclerosis. Cell Transplant 2015; 24(1): 63–72.

12.

Del Papa

DiLuca

Sambataro

et al . Regional implantation of autologous adipose tissue-derived cells induces a prompt healing of long-lasting indolent digital ulcers in patients with systemic sclerosis. Cell Transplant 2015; 24(11): 2297–2305.

13.

Couet

Okamoto

et al . Identification of peptide and protein ligands for the caveolin-scaffolding domain. J Biol Chem 1997; 272(10): 6525–6533.

14.

Le Saux

Teeters

Miyasato

et al . The role of caveolin-1 in pulmonary matrix remodeling and mechanical properties. Am J Physiol Lung Cell Mol Physiol 2008; 295(6): L1007–L1017.

15.

Oka

Yamamoto

Schwencke

et al . Caveolin interaction with protein kinase C. Isoenzyme-dependent regulation of kinase activity by the caveolin scaffolding domain peptide. J Biol Chem 1997; 272(52): 33416–33421.

16.

Razani

Zhang

Bitzer

et al . Caveolin-1 regulates transforming growth factor (TGF)-beta/SMAD signaling through an interaction with the TGF-beta type I receptor. J Biol Chem 2001; 276(9): 6727–6738.

17.

Rybin

Steinberg

SF.

Activated protein kinase C isoforms target to cardiomyocyte caveolae: stimulation of local protein phosphorylation. Circ Res 1999; 84(9): 980–988.

18.

Tourkina

Gooz

Pannu

et al . Opposing effects of protein kinase Calpha and protein kinase Cepsilon on collagen expression by human lung fibroblasts are mediated via MEK/ERK and caveolin-1 signaling. J Biol Chem 2005; 280(14): 13879–13887.

19.

Wang

Huang

Lin

et al . Increased circulating fibrocytes in asthma with chronic airflow obstruction. Am J Respir Crit Care Med 2008; 178(6): 583–591.

20.

Del Galdo

Sotgia

de Almeida

et al . Decreased expression of caveolin 1 in patients with systemic sclerosis: crucial role in the pathogenesis of tissue fibrosis. Arthritis Rheum 2008; 58(9): 2854–2865.

21.

Kasper

Reimann

Hempel

et al . Loss of caveolin expression in type I pneumocytes as an indicator of subcellular alterations during lung fibrogenesis. Histochem Cell Biol 1998; 109(1): 41–48.

22.

Lee

Perry

Heywood

et al . Caveolin-1 regulates chemokine receptor 5-mediated contribution of bone marrow-derived cells to dermal fibrosis. Front Pharmacol 2014; 5: 140.

23.

Lee

Reese

Bonner

et al . Bleomycin delivery by osmotic minipump: similarity to human scleroderma interstitial lung disease. Am J Physiol Lung Cell Mol Physiol 2014; 306(8): L736–L748.

24.

Tourkina

Richard

Oates

et al . Caveolin-1 regulates leucocyte behaviour in fibrotic lung disease. Ann Rheum Dis 2010; 69(6): 1220–1226.

25.

Reese

Lee

Bonner

et al . Fibrocytes in the fibrotic lung: altered phenotype detected by flow cytometry. Front Pharmacol 2014; 5: 141.

26.

Tourkina

Bonner

Oates

et al . Altered monocyte and fibrocyte phenotype and function in scleroderma interstitial lung disease: reversal by caveolin-1 scaffolding domain peptide. Fibrogenesis Tissue Repair 2011; 4(1): 15.

27.

Tourkina

Richard

Gooz

et al . Antifibrotic properties of caveolin-1 scaffolding domain in vitro and in vivo. Am J Physiol Lung Cell Mol Physiol 2008; 294(5): L843–L861.

28.

Wang

Zhang

Kim

et al . Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis. J Exp Med 2006; 203(13): 2895–2906.

29.

Tahir

Park

Thompson

TC.

Caveolin-1 regulates VEGF-stimulated angiogenic activities in prostate cancer and endothelial cells. Cancer Biol Ther 2009; 8(23): 2286–2296.

30.

Tahir

Yang

Goltsov

et al . Tumor cell-secreted caveolin-1 has proangiogenic activities in prostate cancer. Cancer Res 2008; 68(3): 731–739.

31.

Bucci

Gratton

Rudic

et al . In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation. Nat Med 2000; 6(12): 1362–1367.

32.

Bernatchez

Bauer

et al . Dissecting the molecular control of endothelial NO synthase by caveolin-1 using cell-permeable peptides. Proc Natl Acad Sci U S A 2005; 102(3): 761–766.

33.

Cohen

Park

Woodman

et al . Caveolin-1 null mice develop cardiac hypertrophy with hyperactivation of p42/44 MAP kinase in cardiac fibroblasts. Am J Physiol Cell Physiol 2003; 284(2): C457–C474.

34.

Drab

Verkade

Elger

et al . Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science 2001; 293(5539): 2449–2452.

35.

Razani

Engelman

Wang

et al . Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem 2001; 276(41): 38121–38138.

36.

Pleasant-Jenkins

Reese

Chinnakkannu

et al . Reversal of maladaptive fibrosis and compromised ventricular function in the pressure overloaded heart by a caveolin-1 surrogate peptide. Lab Invest 2017; 97(4): 370–382.

37.

Cras

Farge

Carmoi

et al . Update on mesenchymal stem cell-based therapy in lupus and scleroderma. Arthritis Res Ther 2015; 17: 301.

38.

Algeri

Conforti

Pitisci

et al . Mesenchymal stromal cells and chronic inflammatory bowel disease. Immunol Lett 2015; 168(2): 191–200.

39.

Vanneaux

Farge-Bancel

Lecourt

et al . Expression of transforming growth factor β receptor II in mesenchymal stem cells from systemic sclerosis patients. BMJ Open 2013; 3(1): e001890.

40.

Capelli

Zaccara

Cipriani

et al . Phenotypical and functional characteristics of in vitro-expanded adipose-derived mesenchymal stromal cells from patients with systematic sclerosis. Cell Transplant 2017; 26(5): 841–854.

41.

Peng

Chen

et al . Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Dev 2003; 17(11): 1352–1365.

42.

Fleischmajer

Damiano

Nedwich

Scleroderma and the subcutaneous tissue. Science 1971; 171(3975): 1019–1021.

43.

Shan

Liu

Kuang

Fatty acid binding protein 4 expression marks a population of adipocyte progenitors in white and brown adipose tissues. FASEB J 2013; 27(1): 277–287.

44.

Rehan

Sugano

Wang

et al . Evidence for the presence of lipofibroblasts in human lung. Exp Lung Res 2006; 32(8): 379–393.

45.

Zhang

Xie

Zhou

et al . Involvement of TLR4 in oxidized LDL/β2GPI/anti-β2GPI-induced transformation of macrophages to foam cells. J Atheroscler Thromb 2014; 21(11): 1140–1151.

46.

Cipriani

Di Benedetto

Capece

et al . Impaired Cav-1 expression in SSc mesenchymal cells upregulates VEGF signaling: a link between vascular involvement and fibrosis. Fibrogenesis Tissue Repair 2014; 7: 13.

47.

Cipriani

Guiducci

Miniati

et al . Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis. Arthritis Rheum 2007; 56(6): 1994–2004.

48.

Cipriani

Di Benedetto

Liakouli

et al . Mesenchymal stem cells (MSCs) from scleroderma patients (SSc) preserve their immunomodulatory properties although senescent and normally induce T regulatory cells (Tregs) with a functional phenotype: implications for cellular-based therapy. Clin Exp Immunol 2013; 173(2): 195–206.

49.

Wang

Liu

Fan

et al . IGFBP2 enhances adipogenic differentiation potentials of mesenchymal stem cells from Wharton’s jelly of the umbilical cord via JNK and Akt signaling pathways. PLoS ONE 2017; 12(8): e0184182.

50.

Blouin

Le Lay

Eberl

et al . Lipid droplet analysis in caveolin-deficient adipocytes: alterations in surface phospholipid composition and maturation defects. J Lipid Res 2010; 51(5): 945–956.